AI Article Synopsis

  • COVID-19 patients with pre-existing conditions like hypertension and heart failure face worse health outcomes, and ACE2, a key enzyme for virus entry, is found in various heart cell types, including cardiomyocytes.* -
  • By analyzing single-cell RNA sequencing data, researchers found that in failing hearts, the number of ACE2-positive cardiomyocytes and their expression levels of ACE2 significantly increase, suggesting a potential link to heart failure progression.* -
  • The study revealed that ACE2 expression in cardiomyocytes correlates with increased levels of brain natriuretic peptides and is associated with a higher risk of severe outcomes and mortality in COVID-19 patients, indicating that ACE2+ cells may be more susceptible to viral infection.*

Article Abstract

Background: COVID-19 patients with comorbidities such as hypertension or heart failure (HF) are associated with poor clinical outcomes. Angiotensin-converting enzyme 2 (ACE2), the critical enzyme for SARS-CoV-2 infection, is broadly expressed in many organs including heart. However, the cellular distribution of ACE2 in the human heart, particularly the failing heart is unknown.

Methods: We analyzed single-cell RNA sequencing (scRNA-seq) data in both normal and failing hearts, and characterized the ACE2 gene expression profile in various cell subsets, especially in cardiomyocyte subsets, as well as its interaction with gene networks relating to various defense and immune responses at the single cell level.

Results: The results demonstrated that ACE2 is present in cardiomyocytes (CMs), endothelial cells, fibroblasts and smooth muscle cells in the heart, while the number of ACE2-postive (ACE2+) CMs and ACE2 gene expression in these CMs are significantly increased in the failing hearts. Interestingly, both brain natriuretic peptides (BNP) and atrial natriuretic peptide (ANP) are significantly up-regulated in the ACE2+ CMs. Further analysis shows that ANP, BNP and ACE2 may form a negative feedback loop with a group of genes associated with the development of heart failure. To our surprise, we found that genes related to virus entry, virus replication and suppression of interferon-gamma(IFN-γ)signaling are all up-regulated in CMs in failing hearts, and the increases were significantly higher in ACE2+ CMs as compared with ACE2 negative (ACE2-) CMs, suggesting that these ACE2+ CMs may be more vulnerable to virus infection. Since ACE2 expression is correlated with BNP expression, we further performed retrospective analysis of the plasma BNP levels and clinic outcome of 91 COVID-19 patients from a single-center. Patients with higher plasma BNP were associated with significantly higher mortality rate and expression levels of inflammatory and infective markers such as procalcitonin and C-reactive protein.

Conclusion: In the failing heart, the upregulation of ACE2 and virus infection associated genes, as well as the increased expression of ANP and BNP could facilitate SARS-CoV-2 virus entry and replication in these vulnerable cardiomyocyte subsets. These findings may advance our understanding of the underlying molecular mechanisms of myocarditis associated with COVID-19.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7241106PMC
http://dx.doi.org/10.1101/2020.04.30.20081257DOI Listing

Publication Analysis

Top Keywords

ace2+ cms
16
heart failure
12
failing hearts
12
ace2
10
heart
8
covid-19 patients
8
failing heart
8
ace2 gene
8
gene expression
8
cardiomyocyte subsets
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!